Merck MRK
NYSE MRK
$146.77 -0.36 (-0.24%)
At close: Sep 18, 2026 · 4:00 PM EDT

Merck (MRK) Income from Non-Controlling Interests (2009 - 2026)

Merck's (MRK) quarterly Income from Non-Controlling Interests came in at -$2.0 million in Q2 2026, down 300.0% year-over-year from $1.0 million in Q2 2025, and up 33.33% quarter-over-quarter from -$3.0 million in Q1 2026.

Analysis

Merck (MRK) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Merck (MRK) has reported Income from Non-Controlling Interests for 18 consecutive years, with -$2.0 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Income from Non-Controlling Interests fell 300.0% year-over-year to -$2.0 million in Q2 2026; TTM through Jun 2026 was -$4.0 million, a 133.33% decrease from a year earlier, with the FY2025 full-year figure at $9.0 million, down 43.75% from the prior year.
  • Income from Non-Controlling Interests was -$2.0 million for Q2 2026 at Merck, up from -$3.0 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $6.0 million in Q2 2024 and troughed at -$3.0 million in Q1 2022.
  • A 5-year average of $2.3 million and a median of $3.0 million in 2023 frame the typical range for Income from Non-Controlling Interests.
  • Across the five-year window, Income from Non-Controlling Interests jumped 400.0% in 2022 and sank 300.0% in 2026, its largest moves.
  • Over 5 years, Income from Non-Controlling Interests stood at $1.0 million in 2022, then jumped by 400.0% to $5.0 million in 2023, then tumbled by 80.0% to $1.0 million in 2024, then slumped by 200.0% to -$1.0 million in 2025, then sank by 100.0% to -$2.0 million in 2026.
  • The last three Income from Non-Controlling Interests figures came in at -$2.0 million (Q2 2026), -$3.0 million (Q1 2026), and -$1.0 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn 3.00 Mn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn -2.00 Mn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -7.00 Mn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn 10.00 Mn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -1.00 Mn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn 39.52 Mn
8 Revolution Medicines 40.91 Bn 40.91 Bn - -
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.00 Mn
Mar 31, 2026 -3.00 Mn
Dec 31, 2025 -1.00 Mn
Sep 30, 2025 2.00 Mn
Jun 30, 2025 1.00 Mn
Mar 31, 2025 6.00 Mn
Dec 31, 2024 1.00 Mn
Sep 30, 2024 4.00 Mn
Jun 30, 2024 6.00 Mn
Mar 31, 2024 5.00 Mn
Sep 30, 2023 5.00 Mn
Jun 30, 2023 3.00 Mn
Mar 31, 2023 4.00 Mn
Dec 31, 2022 1.00 Mn
Sep 30, 2022 5.00 Mn
Jun 30, 2022 5.00 Mn
Mar 31, 2022 -3.00 Mn
Dec 31, 2021 4.00 Mn
Sep 30, 2021 4.00 Mn
Jun 30, 2021 1.00 Mn